Assembly Biosciences (ASMB)

• Market cap: $508M
• 1 day: -3.25%
• 5 days: -4.15%
• 1 month: 1.83%
• 3 months: -9.51%
• 6 months: -7.28%
• Year to date: -24.12%
• 1 year: 37.1%
• 5 years: -40.22%
• 10 years: -64.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Employees: 73